Dr. Todd D. Levine, MD
Neurology (Neurology Physician)
5090 N. 40th St, Ste 250
Phoenix, AZ 85018
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 230
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Duke University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
AZ license 26977
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Honor Health John C. Lincoln Medical Center Phoenix, AZ
- Honorhealth Scottsdale Osborn Medical Center Scottsdale, AZ
- Honorhealth Scottsdale Thompson Peak Med Ctr Scottsdale, AZ
Medical groups
- Honorhealth Ambulatory (630 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 230
- Services billed
- 4,664
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 173 | 121 |
| Established patient office or other outpatient visit, 20-29 minutes | 140 | 110 |
| Testing of autonomic (sympathetic) nervous system function | 16 | 16 |
| Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | 16 | 16 |
| Established patient office or other outpatient visit, 40-54 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gamunex-C (immune globul g/gly/iga avg 46) | 249 |
| Gabapentin Other prescribers in Phoenix, AZ | 148 |
| Prednisone Other prescribers in Phoenix, AZ | 137 |
| Pregabalin Other prescribers in Phoenix, AZ | 116 |
| Duloxetine Hcl Other prescribers in Phoenix, AZ | 110 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 106 |
| Diazepam Other prescribers in Phoenix, AZ | 85 |
| Baclofen Other prescribers in Phoenix, AZ | 75 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 72 |
| Pyridostigmine Bromide Other prescribers in Phoenix, AZ | 72 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 22 payments worth $53,877 in total to this clinician.
| Csl Behring | $43,859 |
|---|---|
| Grifols USA, LLC | $8,291 |
| Grifols Shared Services North America, Inc. | $1,694 |
| Adma Biomanufacturing LLC | $33.59 |
| Compensation for services other than consulting (speaking, faculty) | $31,620 |
|---|---|
| Travel and Lodging | $14,173 |
| Consulting Fee | $7,696 |
| Food and Beverage | $365 |
| Education | $23.42 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Csl Behring Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $28,000 |
| Csl Behring Sep 27, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $9,235 |
| Grifols USA, LLC Nov 22, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $6,000 |
| Csl Behring Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) Hizentra · Immunology | $3,620 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $1,958 |
| Grifols Shared Services North America, Inc. Sep 29, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $1,663 |
| Csl Behring Sep 29, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $1,042 |
| Csl Behring Oct 5, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $367 |
| Csl Behring Sep 29, 2025 | Travel and Lodging Privigen · Immunology · travel to Saga, Japan · in-kind | $306 |
| Csl Behring Oct 5, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $300 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Grifols USA, LLC Nov 22, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $6,000 |
| Grifols USA, LLC Nov 22, 2025 | Travel and Lodging Gamunex-C · Immunology and Neurology · travel to Raleigh, NC · in-kind | $1,958 |
| Csl Behring Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) | $28,000 |
| Csl Behring Oct 23, 2025 | Travel and Lodging travel to Scottsdale, AZ | $195 |
| Csl Behring Oct 23, 2025 | Travel and Lodging travel to Honolulu, HI | $85.00 |
| Csl Behring Oct 5, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $367 |
| Csl Behring Oct 5, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $300 |
| Csl Behring Oct 3, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $140 |
| Csl Behring Oct 1, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $140 |
| Csl Behring Sep 30, 2025 | Travel and Lodging Privigen · Immunology · travel to Saga, Japan · in-kind | $30.56 |
| Grifols Shared Services North America, Inc. Sep 29, 2025 | Consulting Fee Gamunex-C · Immunology and Neurology | $1,663 |
| Csl Behring Sep 29, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $1,042 |
| Csl Behring Sep 29, 2025 | Travel and Lodging Privigen · Immunology · travel to Saga, Japan · in-kind | $306 |
| Csl Behring Sep 29, 2025 | Travel and Lodging Privigen · Immunology · travel to Saga, Japan · in-kind | $217 |
| Csl Behring Sep 29, 2025 | Travel and Lodging Privigen · Immunology · travel to Saga, Japan · in-kind | $156 |
| Csl Behring Sep 27, 2025 | Travel and Lodging Privigen · Immunology · travel to Tokyo, Japan · in-kind | $9,235 |
| Csl Behring Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) Hizentra · Immunology | $3,620 |
| Csl Behring Jun 16, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
| Adma Biomanufacturing LLC May 12, 2025 | Consulting Fee | $33.59 |
| Csl Behring May 1, 2025 | Education Hizentra · Immunology · in-kind | $11.71 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $283,027 in research payments for these studies, mostly to the institutions running them.
- A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05070858 - A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Imm…
Argenx US, Inc. - A Phase 3 Randomized, Placebo-Controlled Trial of Tofersen in Adults with a Confirmed Mutation in the Superoxide Dismutase 1 Mutation Gene Who Are Clinically Presymptomatic for Amyotrophic Lateral Sclerosis with a Lon…
Biogen, Inc. - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Genzyme Corporation · Completed · NCT04458051 - A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc. - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB SA · Completed · NCT05514873 - A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Acti…
Argenx US, Inc. - Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
Alexion Pharmaceuticals, Inc. - Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Argenx US, Inc. - A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.